Dare Bioscience, Inc. (DARE) — Financial statements
Income statement, balance sheet, and cash flow for Dare Bioscience, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1↑10429.4% | 0.01↓99.7% | 3↓71.9% | 10 | 0.00 | |
| Cost of Revenue | 2↓82.9% | 14↓33.9% | 22↓28.2% | 30↑30042.2% | 0.10 | |
| Gross Profit | -1↑90.1% | -14↑24.1% | -19↑6.5% | -20↓20042.2% | -0.10 | |
| Operating Expenses | ||||||
| R&D Expenses | 5,523↑38782.6% | 14↓34.0% | 22↓28.3% | 30↓1.9% | 31 | |
| General & Administrative Expenses | 9↑4.9% | 8↓26.1% | 11↑6.3% | 11↑36.6% | 8 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 0.80↑33.3% | 0.60↑0.0% | 0.60↑7.0% | 0.56 | |
| SG&A Expenses | 9↓4.3% | 9↓23.1% | 12↑5.9% | 11↑34.6% | 8 | |
| Other Expenses | -5,520↓38758.8% | -14↑33.4% | -21↑29.0% | -30↓3004221800.0% | 0.00 | |
| Operating Expenses | 12↑32.5% | 9↓24.4% | 12↑7.7% | 11↓71.1% | 39 | |
| Total Costs & Expenses | 15↓37.8% | 23↓30.5% | 34↓18.5% | 41↑5.9% | 39 | |
| Operating Results | ||||||
| Operating Income | -14↑42.2% | -23↑24.2% | -31↑1.4% | -31↑19.7% | -39 | |
| Depreciation & Amortization | 2↑4983.0% | 0.04↑10.3% | 0.04↑58.5% | 0.02↓8.4% | 0.03 | |
| EBITDA | -11↑51.3% | -23↑23.8% | -31↑2.1% | -31↑19.7% | -39 | |
| EBIT | -14↑42.2% | -23↑23.7% | -31↑2.1% | -31↑19.7% | -39 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.14 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.68 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.82 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -0.20 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.15↓99.2% | 19↑2391.7% | 0.78↑77.8% | 0.44↑17.5% | 0.37 | |
| Income Before Tax | -13↓230.6% | -4↑86.6% | -30↑2.5% | -31↑20.0% | -39 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -13↓230.6% | -4↑86.6% | -30↑2.5% | -31↑20.0% | -39 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -13↓230.6% | -4↑86.6% | -30↑2.5% | -31↑20.0% | -39 | |
| Bottom-Line Net Income | -13↓230.6% | -4↑86.6% | -30↑2.5% | -31↑20.0% | -39 | |
| EPS (Basic) | -1.20↓150.0% | -0.48↑88.4% | -4.15↑5.5% | -4.39↑41.6% | -7.52 | |
| EPS (Diluted) | -1.20↓150.0% | -0.48↑88.4% | -4.15↑5.5% | -4.39↑41.6% | -7.52 | |
| Weighted Average Shares | 112↑1215.6% | 8↑16.8% | 7↑3.2% | 7↑38.3% | 5 | |
| Weighted Average Diluted Shares | 112↑1215.6% | 8↑16.8% | 7↑3.2% | 7↑38.3% | 5 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.